Should I Buy ATRC? ATRC 2026 Analysis

Should You Buy AtriCure Inc (ATRC) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

36.950

1 Day change

-2.17%

52 Week Range

43.180

Analysis Updated At

2026/01/28

Not a good buy right now for a beginner long-term investor who is impatient. ATRC has solid longer-term fundamentals (mid-teens revenue growth, strong gross margin, improving losses) and supportive sell-side tone, but current technicals are weak and insider selling has surged—so the near-term risk/reward is unfavorable at today’s pre-market level (~38.41).

Technical Analysis

Trend/Setup: Slightly bearish-to-neutral near support. - Price vs levels: Pre-market 38.41 is below the pivot (38.886). Immediate support is S1 ~36.69; resistance overhead at ~41.08 then ~42.43. - Momentum: MACD histogram is negative (-0.225) and expanding lower, indicating weakening momentum. - RSI: RSI(6) ~42.7 (neutral, not oversold), so no strong mean-reversion buy signal. - Moving averages: Converging MAs suggests consolidation, but momentum currently tilts down. - Pattern-based odds (provided): ~60% chance of ~-3.13% next day, modest positive skew over 1 month (+3.6%). **Intellectia Proprietary Trading Signals** - [AI Stock Picker](module://ai_stock_pick): No signal on given stock today. - [SwingMax](module://swingmax): No signal on given stock today.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Options sentiment (limited by very low volume): - Positioning: Put/Call OI ratio 0.02 (calls dominate open interest), which is bullish-leaning. - Flow: Put/Call volume ratio 0.0, but today’s total volume is only 1 contract—too thin to read as strong conviction. - Volatility: 30D IV ~59.8% vs historical vol ~36.2% (options pricing implies elevated uncertainty). IV percentile ~30 and IV rank ~16 suggest IV isn’t at extremes versus its own history.

Technical Summary

Sell

Buy

Positive Catalysts

- Analyst support: JPMorgan reiterated Overweight and raised PT to $48 (from $42), indicating improving sell-side confidence.
- Growth: 2025/Q3 revenue +15.84% YoY and gross margin ~75.47% (very strong).
- Event catalyst ahead: Earnings on 2026-02-17 (after hours) can reset expectations if guidance/volume trends are strong.
- Options positioning: Call-heavy open interest can be a tailwind if price starts breaking above ~41.

Neutral/Negative Catalysts

- Insider selling: Insiders are selling and the selling amount increased ~521% over the last month (clear near-term negative signal).
- Technical momentum: MACD weakening and price below pivot; failure to hold ~36.7 support could invite further downside.
- No recent news: Lack of fresh positive catalysts in the last week means price may continue to drift with technicals.
- Elevated implied volatility vs realized: Market pricing implies higher uncertainty into upcoming catalysts (not ideal for an impatient entry).

Financial Performance

Latest quarter: 2025/Q3. - Revenue: $134.27M, up +15.84% YoY (healthy growth). - Profitability: Net income -$0.267M and EPS -$0.01 (still slightly loss-making, but losses appear much smaller than the prior year based on the percentage change provided). - Margins: Gross margin 75.47%, up +0.79% YoY (strong and improving). Overall: Strong top-line growth and excellent margin profile; profitability is near break-even but not consistently positive yet.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent trend: Bullish tilt. On 2025-12-16, JPMorgan raised the price target to $48 from $42 and maintained an Overweight rating. Wall Street pros vs cons: - Pros: Confidence in the growth story (revenue + mid-teens), strong gross margins, and higher PT suggests upside versus current price (~38.41). - Cons: Still near break-even profitability and heavy insider selling can cap enthusiasm and pressure shares in the short term.

6 Analyst Rating

Wall Street analysts forecast ATRC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATRC is 51.83 USD with a low forecast of 45 USD and a high forecast of 64 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

0 Hold

0 Sell

Strong Buy

Current: 37.770

Low

Averages

51.83

High

Current: 37.770

Low

Averages

51.83

High

JPMorgan

NULL -> Overweight

maintain

$42 -> $48

AI Analysis

2025-12-16

Reason

JPMorgan

Price Target

$42 -> $48

AI Analysis

2025-12-16

maintain

NULL -> Overweight

Reason

JPMorgan raised the firm's price target on AtriCure to $48 from $42 and keeps an Overweight rating on the shares. The firm updated the company's model.

Canaccord

William Plovanic

Buy

maintain

$51 -> $53

2025-07-30

Reason

Canaccord

William Plovanic

Price Target

$51 -> $53

2025-07-30

maintain

Buy

Reason

Canaccord analyst William Plovanic raised the firm's price target on AtriCure to $53 from $51 and keeps a Buy rating on the shares. The firm said they reported a very solid Q2, with strength across the rest of the business more than offsetting further degradation of US EPi-Sense/Hybrid. The target increase reflects comp group multiple expansion and increased expectations.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ATRC

Unlock Now

ATRC Should I Buy

ATRC Should I Buy

Should You Buy AtriCure Inc (ATRC) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch